Tim Haines serves as Chairman and Managing Partner at Abingworth, a London-based venture capital firm. See sector focus and contact routes.
Tim Haines serves as Chairman and Managing Partner at Abingworth, a London-based venture capital firm, with over 30 years of international management experience in the life sciences industry across public and private companies. He joined Abingworth in 2005 after leading portfolio company Astex Therapeutics as its Chief Executive for more than five years, where he helped establish it as a leading UK biotechnology firm. Abingworth’s investment focus centers on life sciences, including biotechs and CNS diseases, with prior investments in companies like Alnylam and CRISPR Therapeutics. While specific check sizes and lead/follow behavior for Haines are not publicly detailed, he has held chair and board roles in numerous Abingworth investments including Astex, GammaDelta Therapeutics, and MEDIAN Technologies. Notable portfolio companies associated with his tenure include Astex Therapeutics, CRISPR Therapeutics, and Alnylam. Haines also contributes to the broader ecosystem as a member of Oxford University Innovation’s Investment Advisory Board and formerly served on the BVCA Venture Committee and the Wellcome Trust/NHS Health Innovation Challenge Fund.
Every field above is read from the StartupFundraising investor directory — disclosed location, recorded investments and stated focus — and re-checked as filings arrive. Founders pair it with investors in London when building a target list.
Investors like Tim Haines · Full investor directory · Investor access · Company funding database